Late clinical-stage immuno-oncology company Genelux Corporation (NASDAQ:GNLX) revealed on Monday that it has been granted Fast Track designation by the US Food and Drug Administration (FDA) for Olvi-Vec (olvimulogene nanivacirepvec).
This designation relates to the treatment of patients with platinum resistant/refractory ovarian cancer.
"The Fast Track designation granted for Olvi-Vec underscores its potential to address unmet medical needs in ovarian cancer, a significant recognition as we continue to enrol our Phase 3 OnPrime study," commented Thomas Zindrick, president, vhairman and CEO of Genelux.
The ongoing Phase 3 trial is evaluating the efficacy and safety of Olvi-Vec in combination with platinum-based chemotherapy in patients with platinum-resistant/refractory ovarian cancer.
Fast Track designation expedites the drug development and review process for treatments targeting serious and life-threatening conditions. It includes regular engagements with the FDA review team and the possibility of eligibility for Priority Review and Rolling Review if specific criteria are met.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member